Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour
β Scribed by Karen A. Herd; Tracey Harvey; Alexander A. Khromykh; Robert W. Tindle
- Book ID
- 113945779
- Publisher
- Elsevier Science
- Year
- 2004
- Tongue
- English
- Weight
- 390 KB
- Volume
- 319
- Category
- Article
- ISSN
- 0042-6822
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Although many clinical trials on human papillomavirus (HPV) therapeutic vaccines have been performed, clinical responses have not been consistent. We have addressed mucosal cytotoxic cellular immune responses to HPV16 E7 after oral immunization of mice with recombinant Lactobacillus casei expressing
Expression of human papillomavirus type 16 (HPV 16) fusion proteins LI deltaCE7(1-55) and LI deltaCE7(1-60) (carboxy-terminal deletion of LI replaced by 55 or 60 amino-terminal amino acids of E7) leads to formation of chimeric papillomavirus-like particles (CVLPs). After "infection" of cells by CVLP